PFO Closure Products Lose “Humanitarian Device” Status
This article was originally published in The Gray Sheet
Executive Summary
NMT Medical has a step up on patent foramen ovale closure competitor AGA Medical after both firms got word from FDA that they should remove their limited-release stroke treatments from the U.S. market
You may also be interested in...
Gore Nabs PFO-Closure Approval For Stroke
WL Gore's Cardioform Septal Occluder is now the second device to gain PMA approval to close the patent foramen ovale heart defect, to help prevent repeat ischemic stroke, according to FDA's website.
AGA Medical Pursues Stroke, Migraine Indications And $200 Mil. IPO
AGA Medical hopes to complete a pivotal U.S. trial by year-end assessing its Amplatzer PFO Occluder for prevention of recurrent cryptogenic strokes, the company says in a June 20 prospectus for a planned initial public offering worth up to $200 million
AGA Medical Pursues Stroke, Migraine Indications And $200 Mil. IPO
AGA Medical hopes to complete a pivotal U.S. trial by year-end assessing its Amplatzer PFO Occluder for prevention of recurrent cryptogenic strokes, the company says in a June 20 prospectus for a planned initial public offering worth up to $200 million